How Ruxolitinib Cream Can Help Treat Vitiligo

Research has shown that Ruxolitinib cream could help in treating vitiligo. The American Academy of Dermatology (AAD) recently presented new data that suggests that Ruxolitinib cream can have benign and reasonable advantages for atopic dermatitis.

Earlier, dermatologists had suggested various treatments and precautions to provide color to the skin in the affected area. However, usually these treatments are not permanent. They may include vitamin supplements, keeping safe from the sun, or a topical steroid. Nonetheless, dermatologists are hopeful that Ruxolitinib cream can provide a better solution.

How Ruxolitinib cream can help treat Vitiligo?

Ruxolitinib is a topical JAK 1 & 2 inhibitor. JAK inhibitors have the potential to be a promising treatment option in vitiligo. This implies that the cream will have a better disease controlling opportunity for the patients. However, clinicians must define the limitations before a patient uses the new therapy.

The use of Ruxolitinib cream has gone through an evolution process. Previously, it had been a subject of massive studies in laboratories. But now it has become a part of clinical practice strategies. The doctors who prescribe the medicine to a patient may adjust the precise application of the cream from an 8-week course, where the patient would use the cream daily, to a less frequent use once the 8-week course has ended. Currently, researches are underway to figure out the least amount that can be helpful to control skin diseases through Ruxolitinib cream.

Is Ruxolitinib cream safe?

There were many non-steroid topical treatments in the past that raised questions about the safety and side effects for the patients. There are reports that oral JAK inhibitors had adverse side effects in some patients. Furthermore, there is a chance that the cream can permeate the skin if it is used beyond the 8-weeks’ regimen. Resultantly, it could affect blood flow. Therefore, it is essential that Ruxolitinib cream clear any such doubts about its usage. Studies are underway to clear all such doubts and questions. And it is quite likely that such concerns will be addressed positively. That’s because so far all the data shows that it is exceptionally well-tolerated and the safety data is also considered to be good. It is quite efficient as well.

It is these positive aspects that show that Ruxolitinib cream and the emerging topical JAK inhibitor drug class might as well treat patients with chronic skin diseases, to which there were no treatments in the past.

Future Prospects For Ruxolitinib

Most of the patients of vitiligo have lost hope for a permanent solution. Some of them got accustomed to living with the disease. While others have become exhausted due to trying different medicines without any long-lasting benefits. Nonetheless, Ruxolitinib cream can be a life-changing agent for these patients and a great breakthrough for dermatologists.

Image is for illustrative purposes only